Cadila Healthcare gains on plan to develop vaccines for ‘Congo Virus’ and ‘Ebola Virus’

01 Jan 2015 Evaluate

Cadila Healthcare is currently trading at Rs. 1606.00, up by 7.65 points or 0.48% from its previous closing of Rs. 1598.35 on the BSE.

The scrip opened at Rs. 1610.00 and has touched a high and low of Rs. 1619.00 and Rs. 1600.00 respectively. So far 1108 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 1760.00 on 11-Nov-2014 and a 52 week low of Rs. 730.25 on 06-Jan-2014.

Last one week high and low of the scrip stood at Rs. 1619.00 and Rs. 1556.50 respectively. The current market cap of the company is Rs. 32934.82 crore.

The promoters holding in the company stood at 74.79% while Institutions and Non-Institutions held 14.51% and 10.69% respectively.

Cadila Healthcare is developing vaccines for ‘Congo Virus’ and ‘Ebola Virus’ as a part of Company's vaccine development programme. However, the company has not shared investment details.

Cadila Healthcare operates in areas of active pharmaceutical ingredients (API) to formulations, and animal health products to cosmeceuticals.

 

Zydus Lifesciences Share Price

931.45 -3.75 (-0.40%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×